Price at ₹222.39, 33% above 200 SMA, extended.
Q4 FY2026 results likely released late April/early May 2026.
No specific news for BELRISE.NS; ticker may be illiquid or misidentified.
Revenue CAGR ~15% from FY22 to FY25, TTM revenue 11% above FY25.
Stock rallied 129% in 12 months; 50-day SMA ₹31 above 200-day SMA.
Sell/trim 25-30% at ₹228, stop-loss ₹198 (50-day SMA).
Debt halved to ₹1,418 Cr, but equity diluted 22x to ₹445 Cr.
Debt down 52% but equity diluted 22x; negative FCF of -₹163 Cr.